Lysophosphatidic Acid Receptor Antagonists Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

A lysophosphatidic acid (LPA) is a phospholipid derivative that can act as a signaling molecule. LPA acts as a potent mitogen due to its activation of three high affinity G-protein-coupled receptors called LPAR1, LPAR2, and LPAR3. Dysregulated LPA-signaling has been linked to cancer, and can lead to hyperproliferation, which may contribute to oncogenesis and metastasis. PA might also be associated with pruritus in individuals with cholestatic diseases. Lysophosphatidic acid receptor antagonists act by inhibiting the LPA receptor, thereby preventing it from binding to the signaling molecule lysophosphatidic acid. Lysophosphatidic acid receptor antagonists are in clinical trials for idiopathic pulmonary fibrosis, psoriasis, pulmonary fibrosis, and others. BMS, Horizon Therapeutics, and Apollo Endosurgery are some of the major players in the lysophosphatidic acid receptor antagonists market.

Drugs under the Pipeline for Lysophosphatidic Acid Receptor Antagonists:

• BMS-986278
• BMS-986020
• fipaxalparant (HZN-825)
• BMS-986337
• Lpathomab
• HL-001

Key Market Developments:

• In Mar 2022, Ube Industries and HiLung entered into a collaboration agreement to co-develop and conduct clinical trials for HL-001 in idiopathic pulmonary fibrosis.
• In June 2023, the FDA awarded Orphan Drug Designation to HL-001, an LPA-1 antagonist being developed for idiopathic pulmonary fibrosis by Ube Industries.

Clinical Activity and Developments of Lysophosphatidic Acid Receptor Antagonists:

Currently, there are more than 20 drug products in the lysophosphatidic acid receptor antagonists, including 12 approved drug products and the rest of them are in the clinical development phases.

• In Nov 2022, Horizon Therapeutics initiated enrolment in a phase-I/II open-label extension trial for diffuse scleroderma in the USA for Fipaxalparant.
• In July 2023, Bristol-Myers Squibb presented updated safety and efficacy data from the phase-II trial in idiopathic pulmonary fibrosis for BMS 986278, a LPA antagonist.